


10-13-04

EFW



# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

App. No. : 10/735,601  
 Applicant : Smith et al.  
 Filed : December 12, 2003  
 TC/A.U. : 1635  
 Examiner : Brian A. Whiteman  
 For : MULTI-ANTIGENIC ALPHAVIRUS REPLICON  
 PARTICLES AND METHODS  
 Docket No. : 95-02  
 Customer No.: 23713

Confirmation No. 2496

Commissioner for Patents  
 MAIL STOP AMENDMENT  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for <b>Express Mail</b> in an envelope addressed to: Commissioner for Patents, Mail Stop Amendment, PO Box 1450, Alexandria, VA 22313-1450	
October 12, 2004 Date	<i>Cathy Nelson</i> Cathy Nelson
EV 504060670 US Express Mail Tracking Number	

## INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants respectfully note that additional U. S. patent documents were made of record in an Information Disclosure Statement filed electronically on October 7, 2004.

The Examiner is respectfully requested to consider the references, copies enclosed, which may qualify as prior art. For the Examiner's convenience, the references are listed on the attached Patent and Trademark Office form PTO-1449.

This information is cited in a spirit of forthrightness and cooperation to enable the applicants to obtain that measure of protection for the invention to which there is entitlement. However, no representation is made that the listed art actually qualifies as prior art under the patent statute and the mere use of PTO-1449 is not an admission that all listed references are prior art. No representation is made that applicants know of the best art.

It is believed that this submission does not require the payment of a fee. If this is not correct, please charge any required fee to deposit account no. 07-1969.

Respectfully submitted,



Donna M. Ferber  
Reg. No. 33,878

**GREENLEE, WINNER AND SULLIVAN, P.C.**

5370 Manhattan Circle, Suite 201

Boulder, CO 80303

Telephone: (303) 499-8080

Facsimile: (303) 499-8089

E-mail: [winner@greenwin.com](mailto:winner@greenwin.com)

Attorney Docket No. 95-02

October 12, 2004

OCT 12 2004

Sheet 1 of 3

Substitute for form 1449/PTO, based on PTO/SB/08A and 08B

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Application Number	10/735,601
Filing Date	December 12, 2003
First Named Inventor	Smith et al.
Art Unit	1635
Examiner Name	Brian A. Whiteman
Attorney Docket Number	95-02

GWS 10/12/2004

**U.S. PATENT DOCUMENTS**

Examiner Initial*	Cite No. <sup>1</sup>	Document Number (US-)	Publication Date (MM-DD-YYYY)	Name	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear (or entire document unless noted otherwise)

**FOREIGN PATENT DOCUMENTS**

Examiner Initial*	Cite No. <sup>1</sup>	Foreign Patent Document Number (include WIPO country code)	Publication Date (MM-DD-YYYY)	Name	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear (or entire document unless noted otherwise)	T <sup>2</sup>
	1	WO 92/10578	06/25/1992			
	2	WO 99/08706	02/25/1999			

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initial*	Cite No. <sup>1</sup>	REFERENCE Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	Balasuriya et al. (Feb. 2002) "Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses"; <i>Vaccine</i> 20:1609-1617.	
	2	Barry et al. (2004) "Expression library immunization to discover and improve vaccine antigens"; <i>Immunological Reviews</i> 199:68-83	
	3	Bell et al. (Mar. 1978) "Effect of Low-NaCl Medium on the Envelope Glycoproteins of Sindbis Virus"; <i>J. Virol.</i> 25(3):764-769	
	4	Bergman et al. (Apr. 2003) "Long-Term Survival of Dogs with Advanced Malignant Melanoma after DNA Vaccination with Xenogeneic Human Tyrosinase: A Phase I Trial"; <i>Clin. Cancer Research</i> 9:1284-1290	
	5	Casimiro et al. (Jan. 2002) "Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized immunodeficiency virus type 1 pol gene"; <i>J. Virol.</i> 76:185-195	
	6	Frolov et al. (1996) "Alphavirus-based expression vectors: Strategies and applications"; <i>Proc. Natl. Acad. Sci. USA</i> 93:11371-11377	
	7	Geisbert et al. (May 2002) "Evaluation in Nonhuman Primates of Vaccines against Ebola Virus"; <i>Emerging Infect. Dis.</i> 8(5):503-507	


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional).

<sup>2</sup>Applicant is to place a check mark here or "x" if English language Translation is attached.

Substitute for form 1449/PTO, based on PTO/SB/08A and 08B

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**


Application Number	10/735,601
Filing Date	December 12, 2003
First Named Inventor	Smith et al.
Art Unit	1635
Examiner Name	Brian A. Whiteman
Attorney Docket Number	95-02

GWS 10/12/2004

8	Hahn et al. (1992) "Infectious Sindbis Virus Transient Expression Vectors for Studying Antigen Processing and Presentation," <i>Proc. Natl. Acad. Sci. USA</i> 89:2679-2683
9	Heiser et al. (Feb. 2002) "Autologous Dendritic Cells Transfected with Prostate-Specific Antigen RNA Stimulate CTL Responses Against Metastatic Prostate Tumors," <i>J. Clin. Inv.</i> 109(3):409-417
10	Hevey et al. (1998) "Marburg Virus Vaccines Based upon Alphavirus Replicons Protect Guinea Pigs and Nonhuman Primates"; <i>Virology</i> 251:28-37
11	Kinney et al. (1989) The Full-Length Nucleotide Sequences of the Virulent Trinidad Donkey Strain of Venezuelan Equine Encephalitis Virus and Its Attenuated Vaccine Derivative, Strain TC-83," <i>Virology</i> 170:19-30
12	Koller et al. (Sept. 2001) "A high-throughput alphavirus-based expression cloning system for mammalian cells"; <i>Nature Biotech.</i> 19:851-855
13	Kumamoto et al. (Jan. 2002) "Induction of Tumor-Specific Protective Immunity by <i>in situ</i> Langerhans Cell Vaccine," <i>Nature Biotech.</i> 20:64-69
14	Leitner et al. (Jan.2000) "Enhancement of Tumor-specific Immune Response with Plasmid DNA Replicon Vectors"; <i>Cancer Research</i> 60:51-55
15	Li et al. (October 1996) "Production of infectious recombinant Moloney murine leukemia virus particles in BHK cells using Semliki Forest virus-derived RNA expression vectors." <i>Proc. Natl. Acad. Sci. USA.</i> 93:11658-11663
16	Overwijk et al. (Jan.2001) "Creating therapeutic cancer vaccines: notes from the battlefield"; <i>Trends in Immunol.</i> 22(1):5-7
17	Pardoll, D.M. (May 1998) "Cancer Vaccines"; <i>Nature Medicine Vaccine Supplement</i> 4(5):525-531
18	Pardoll, D.M. (Apr. 2002) Spinning Molecular Immunology into Successful Immunotherapy"; <i>Nature Reviews - Immunology</i> 2:227-238
19	Pushko et al. (1997) "Replicon-Helper systems from Attenuated Venezuelan Equine Encephalitis Virus: Expression of Heterologous Genes <i>in Vitro</i> and Immunization against Heterologous Pathogens <i>in Vivo</i> "; <i>Virology</i> 239:389-401
20	Ragupathi et al. (Aug. 2002) "The case for polyvalent cancer vaccines that induce antibodies"; <i>Expert Rev. Vaccines</i> 1(2):193-206
21	Rayner et al. (Sep.-Oct. 2002) "Alphavirus Vectors and Vaccination," <i>Rev. Med. Virol.</i> 12:279-296
22	Sadanaga et al. (Aug. 2001) "Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas"; <i>Clin. Cancer Res.</i> 7:2277-2284
23	Slepushkin et al. (Sep.-Oct. 2003) "Large scale purification of a lentiviral vector by size exclusion chromatography or mustang Q ion exchange capsule."; <i>Bioprocessing J.</i> p:89-94
24	Waite et al. (Jan. 1970) "Inhibition of Sindbis Virus Production by Media of Low Ionic Strength: Intracellular Events and Requirements for Reversal"; <i>J. Virol.</i> 5:60-71.
25	Ward et al. (Sep. 2002) "Immunotherapeutic Potential of Whole Tumor Cells," <i>Cancer Immunol. Immunother.</i> 51:351-357.


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional).

<sup>2</sup>Applicant is to place a check mark here or "x" if English language Translation is attached.

Substitute for form 1449/PTO, based on PTO/SB/08A and 08B  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application Number	10/735,601
	Filing Date	December 12, 2003
	First Named Inventor	Smith et al.
	Art Unit	1635
	Examiner Name	Brian A. Whiteman
	Attorney Docket Number	95-02



GWS 10/12/2004

26	Wilson et al. (Aug. 2001) "Vaccine Potential of Ebola Virus VP24, VP30, VP35, and VP40 Proteins"; <i>Virology</i> <b>286</b> :384-390	
27	Yamanaka et al. (Sept. 2002) Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12"; <i>J. Neurosurg.</i> <b>97</b> :611-618.	
28	Yamanaka et al. (Mar. 2001) "Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki Forest virus-mediated complementary DNA"; <i>J. Neurosurg.</i> <b>94</b> :474-481.	
29	Ying et al. (1999) "Cancer therapy using a self-replicating RNA vaccine"; <i>Nature Medicine</i> <b>5</b> (7):823-827	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).

<sup>2</sup> Applicant is to place a check mark here or "x" if English language Translation is attached.